The imbalance between osteoprotegerin and cathepsin K in the serum of patients with longstanding rheumatoid arthritis

Rheumatology International

Volumn 28, Issue 7, 2008, Pages 637-641

  Skoumal, Martin ^a,b   Haberhauer, Günther ^a   Kolarz, Gernot ^a   Hawa, Gerhard ^c   Woloszczuk, Wolfgang ^d   Klingler, Anton ^e   Varga, Franz ^b   Klaushofer, Klaus ^b  

^a DANUBE UNIVERSITY KREMS   (Austria)

^b HANUSCH HOSPITAL   (Austria)

^c Biomedica Medizinprodukte GmbH and Co KG   (Austria)

^d LUDWIG BOLTZMANN INSTITUTE FOR LUNG VASCULAR RESEARCH   (Austria)

^e UNIVERSITY HOSPITAL INNSBRUCK   (Austria)

Author keywords

Cathepsin K; Osteoprotegerin; Receptor activator of NF kappa B ligand; Rheumatoid arthritis

Indexed keywords

CATHEPSIN K; LEFLUNOMIDE; METHOTREXATE; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN;

ADULT; AGED; ARTICLE; BONE DEFECT; CONTROLLED STUDY; HUMAN; LABORATORY TEST; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; RHEUMATOID ARTHRITIS;

ADULT; AGED; AGED, 80 AND OVER; ARTHRITIS, RHEUMATOID; BIOLOGICAL MARKERS; CATHEPSINS; HUMANS; MIDDLE AGED; OSTEOPROTEGERIN; RANK LIGAND;

EID: 41849102403     PISSN: 01728172     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00296-007-0506-3     Document Type: Article

References (29)

1. Haynes DR, Barg E, Crotti TN, Holding C, Weedon H et al (2003) Osteoprotegerin expression in synovial tissue from patients with rheumatoid arthritis, spondylarthropathies and osteoarthritis and normal controls. Rheumatology 42:123-34
2. Crotti TN, Smith MD, Weedon H, Ahern MJ, Findlay DM, Kraan M et al (2002) Receptor activator NF-kappa B ligand (RANKL) expression in synovial tissue from patients with rheumatoid arthritis, spondylarthropathy, osteoarthritis, and from normal patients: semiquantitative and quantitative analysis. Ann Rheum Dis 61:1047-1054
3. Hou WS, Li Z, Keyszer G, Weber E, Levy R, Klein MJ, Gravallese EM, Goldring SR, Bromme D (2002) Comparison of cathepsin K and S expression within the rheumatoid and osteoarthritic synovium. Arthritis Rheum 46(3):663-674
4. Kaneko M, Tomita T, Nakase T, Ohsawa Y, Seki H, Takeuchi E, Takano H, Shi K, Takahi K, Kominami E, Uchiyama Y, Yoshikawa H, Ochi T (2001) Expression of proteinases and inflammatory cytokines in subchondral bone regions in the destructive joint of rheumatoid arthritis. Rheumatology (Oxford) 40(3):247-255
5. Skoumal M, Kolarz G, Woloszczuk W, Hawa G, Klingler A (2005) Serum cathepsin K levels of patients with destructive rheumatoid arthritis: correlation with radiological destruction. Arthritis Res Ther 7:R65-R70
6. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, Healey LA, Kaplan SR, Liang MH (1988) The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 31:315-324
7. Ritchie DM, Boyle JA, McInnes JM, Jasani MK, Dalakos TG, Grieveson P (1968) Clinical studies with an articular index for the assessments of joint tenderness in patients with rheumatoid arthritis. Q J Med 147:393-406
8. Smolen JS, Breedveld FC, Eberl G (1995) Validity and reliability of the twenty-eight-joint count for the assessment of rheumatoid arthritis. Arthritis Rheum 38:38-43
9. Larsen A, Dale K, Eek M (1976) Radiographic evaluation of rheumatoid arthritis and related conditions by standard reference films. Acta Radiol Diagn 18:481-491
10. Kudlacek S, Schneider P, Pietschmann P, Woloszczuk W, Willvonseder R (2003) Serum levels of osteoprotegerin increase with age in a healthy adult population. Bone 32:681-686
11. Hawa G, Brinskelle-Schmal N, Glatz K, Maitzen S, WoloszczukW (2003) Immunoassay for soluble RANKL (receptor activator of NF-κB ligand) in serum. Clin Lab 49(9-10):461-463
12. Skoumal M, Kolarz G, Woloszczuk W, Hawa G, Klingler A (2004) Serum osteoprotegerin but not receptor activator of NF-kappa B ligand correlates with the Larsen score in rheumatoid arthritis. Ann Rheum Dis 63(2):216-217
13. Schett G, Redlich K, Smolen JS (2003) The role of osteoprotegerin in arthritis. Arthritis Res Ther 5:239-245
14. Collin-Osdoby P, Rothe L, Anderson F, Nelson M, Maloney W, Osdoby P (2001) Receptor activator of NF-kappa B and osteoprotegerin expression by human microvascular endothelial cells, regulation by inflammatory cytokines, and role in human osteoclastogenesis. J Biol Chem 276:20659-20672
15. Jones DH, Kong YY, Penninger JM (2002) Role of RANKL and RANK in bone loss and arthritis. Ann Rheum Dis 61(Suppl II):ii32-ii39
16. Li J, Sarosi I, Yan XQ, Morony S, Capparelli C, Tan HL, McCabe S (1997) RANK is the intrinsinc hematopoietic cell surface receptor that controls osteoclastogenesis and regulation of bone mass and calcium metabolism. Proc Natl Acad Sci USA 97(4):1566-1571
17. Kong YY, Yoshida H, Sarosi I, Tan HL, Timms E, Capparelli C, Morony S, Oliveira-dos-Santos AJ, Van G, Itie A, Khoo W, Wakeham A, Dunstan CR, Lacey DL, Mak TW, Boyle WJ, Penninger JM (1999) OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis. Nature 397:315-323
18. Komuro H, Olee T, Kuhn K, Quach J, Brinson DC, Shikhman A, Valbracht J, Creighton-Achermann L, Lotz M (2001) The osteoprotegerin/receptor activator of nuclear factor kappa B/receptor activator of nuclear factor kappa B ligand system in cartilage. Arthritis Rheum 44:2768-2776
19. Ziolkowska M, Kurowska M, Radzikowska A, Luszczykiewicz G, Wieland P, Dziewczopolski W, Filipowicz-Sosnowska A, Pazdur J, Szechinski J, Kowalczewski J, Rell-Bakalarska M, Maslinski W (2002) High levels of osteoprotegerin and soluble receptor activator of nuclear factor kappa B ligand in serum of rheumatoid arthritis patients and their normalization after anti-tumor necrosis factor alpha treatment. Arthritis Rheum 46(7):1744-1753
20. Marotte H, Maslinski W, Miossec P (2005) Circulating tumor necrosis factor-alpha bioactivity in rheumatoid arthritis patients treated with Infliximab: link to clinical response. Arthritis Res Ther 7:R149-R155
21. Haynes DR, Crotti TN, Loric M, Bain GI, Atkins GJ, Findlay DM (2001) Osteoprotegerin and receptor activator of nuclear factor-(B ligand (RANKL) regulate osteoclast formation by cells in the human rheumatoid arthritic joint. Rheumatology 40:623-630
22. Hofbauer LC, Heufelder AC (2001) Role of receptor activator of nuclear factor-(B ligand and osteoprotegerin in bone cell biology. J Mol Med 79:243-253
23. Wittrant Y, Couillaud S, Theoleyre S, Dunstan C, Heymann D, Redini F (2002) Osteoprotegerin differentially regulates protease expression in osteoclast cultures. Biochem Biophys Res Commun 293(1):38-44
24. Troen BR (2004) The role of cathepsin K in normal bone resorption. Drug News Perspect 17(1):19-28
25. Hou WS, Li Z, Buttner FH, Bartnik E, Bromme D (2003) Cleavage site specifity of cathepsin K toward cartilage proteoglycans and protease complex formation. Biol Chem 384(6):691-697
26. Hummel KM, Petrow PK, Franz JK, Maller-Ladner U, Aicher WK, Gay RE, Brämme D, Gay S (1998) Cysteine protease cathepsin K mRNA is expressed in synovium of patients with rheumatoid arthritis and is detected at sites of synovial bone destruction. J Rheumatol 25(10):1887-1894
27. Votta BJ, Levy MA, Badger A, Bradbeer J, Dodds RA, James IE, Thompson S, Bossaard MJ, Carr T, Connor JR, Tomaszek TA, Szewczuk L, Drake FH, Veber DF, Gowen M (1997) Peptide aldehyde inhibitor of cathepsin K inhibit bone resorption both in vitro and in vivo. J Bone Miner Res 12(9):1396-1406
28. Tavares FX, Boncek V, Deaton DN, Hassell AM, Long ST, Miller AB, Payne AA, Miller LR, Shewchuk LM, Wells-Knecht K, Willard DH, Wright LL, Zhou HQ (2004) Design of potent, selective and orally bioavailable inhibitors of cysteine protease cathepsin K. J Med Chem 47(3):588-599
29. Skoumal M, Kolarz G, Haberhauer G, Woloszczuk W, Hawa G, Klingler A (2005) Osteoprotegerin and the receptor activator of NF-kappa B ligand in the serum and synovial fluid. A comparison of patients with longstanding rheumatoid arthritis and osteoarthritis. Rheumatol Int 26(1):63-69